应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01167 加科思-B
交易中 07-22 15:44:14
5.320
+0.250
+4.93%
最高
5.380
最低
5.080
成交量
351.08万
今开
5.080
昨收
5.070
日振幅
5.92%
总市值
41.60亿
流通市值
41.60亿
总股本
7.82亿
成交额
1,842万
换手率
0.45%
流通股本
7.82亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
加科思-B7月21日回购9.84万股,涉资约49.86万港元
公告速递 · 07-21 20:02
加科思-B7月21日回购9.84万股,涉资约49.86万港元
加科思-B(01167)7月21日斥资49.86万港元回购9.84万股
智通财经 · 07-21 19:52
加科思-B(01167)7月21日斥资49.86万港元回购9.84万股
港股异动 | 加科思-B(01167.HK)午后涨超8% JAB-23E73联合化疗试验完成首例患者给药
智通财经 · 07-20 14:12
港股异动 | 加科思-B(01167.HK)午后涨超8% JAB-23E73联合化疗试验完成首例患者给药
加科思-B(01167):完成泛KRAS抑制剂JAB-23E73联合化疗用于KRAS突变胰腺癌一线 治疗之Ib/III期临床试验在中国的首例患者给药
智通财经 · 07-20 06:42
加科思-B(01167):完成泛KRAS抑制剂JAB-23E73联合化疗用于KRAS突变胰腺癌一线 治疗之Ib/III期临床试验在中国的首例患者给药
加科思-B(01167)宣布JAB-23E73联合方案在华Ib/III期试验完成首例给药
公告速递 · 07-20 06:41
加科思-B(01167)宣布JAB-23E73联合方案在华Ib/III期试验完成首例给药
加科思-B回购10.5万股股份,总额约48.78万港元
公告速递 · 07-17
加科思-B回购10.5万股股份,总额约48.78万港元
加科思-B(01167)7月17日斥资48.8万港元回购10.5万股
智通财经 · 07-17
加科思-B(01167)7月17日斥资48.8万港元回购10.5万股
加科思-B回购约10.17万股股份,总额约49.87万港元
公告速递 · 07-13
加科思-B回购约10.17万股股份,总额约49.87万港元
加科思-B(01167)7月13日耗资约49.87万港元回购10.17万股
智通财经 · 07-13
加科思-B(01167)7月13日耗资约49.87万港元回购10.17万股
加科思-B回购10.11万股,耗资约49.94万港元
公告速递 · 07-09
加科思-B回购10.11万股,耗资约49.94万港元
加科思-B:7月8日回购101,700股,耗资约49.88万港元
公告速递 · 07-08
加科思-B:7月8日回购101,700股,耗资约49.88万港元
加科思-B(01167.HK)7月8日斥资49.9万港元回购10.17万股
智通财经 · 07-08
加科思-B(01167.HK)7月8日斥资49.9万港元回购10.17万股
加科思-B回购101,100股股份,合计耗资约49.92万港元
公告速递 · 07-07
加科思-B回购101,100股股份,合计耗资约49.92万港元
加科思-B(01167)7月7日斥资49.92万港元回购10.11万股
智通财经 · 07-07
加科思-B(01167)7月7日斥资49.92万港元回购10.11万股
加科思-B更新6月股份变动月报表,当月回购976,500股
公告速递 · 07-07
加科思-B更新6月股份变动月报表,当月回购976,500股
加科思-B:6月24日回购10.86万股,涉资约46.82万港元
公告速递 · 06-24
加科思-B:6月24日回购10.86万股,涉资约46.82万港元
加科思-B(01167)6月24日斥资46.82万港元回购10.86万股
智通财经 · 06-24
加科思-B(01167)6月24日斥资46.82万港元回购10.86万股
加科思-B回购111,600股,涉资约49.89万港元
公告速递 · 06-22
加科思-B回购111,600股,涉资约49.89万港元
加科思-B(01167)6月22日耗资约49.89万港元回购11.16万股
智通财经 · 06-22
加科思-B(01167)6月22日耗资约49.89万港元回购11.16万股
加科思-B回购11.34万股股份,耗资约49.86万港元
公告速递 · 06-18
加科思-B回购11.34万股股份,耗资约49.86万港元
加载更多
公司概况
公司名称:
加科思-B
所属市场:
SEHK
上市日期:
--
主营业务:
加科思药业集团有限公司是一家主要从事临床阶段新药研发的投资控股公司。该公司主要负责创新肿瘤疗法的自主发现和开发。该公司主要药物开发项目包括JAB-21822及JAB-3312临床阶段的变构SHP2抑制剂。该公司主要在中国市场开展业务。
发行价格:
--
{"stockData":{"symbol":"01167","market":"HK","secType":"STK","nameCN":"加科思-B","latestPrice":5.32,"timestamp":1784706210159,"preClose":5.07,"halted":0,"volume":3510786,"delay":0,"changeRate":0.049309664694280074,"floatShares":782000000,"shares":782000000,"eps":-0.21816556054191363,"marketStatus":"交易中","change":0.25,"latestTime":"07-22 15:44:14","open":5.08,"high":5.38,"low":5.08,"amount":18423092,"amplitude":0.059172,"askPrice":5.33,"askSize":29700,"bidPrice":5.31,"bidSize":14100,"shortable":3,"etf":0,"ttmEps":-0.21816556054191363,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784707800000},"marketStatusCode":2,"adr":0,"listingDate":1608480000000,"exchange":"SEHK","adjPreClose":5.07,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":0.989145,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01167","defaultTab":"news","newsList":[{"id":"1135489982","title":"加科思-B7月21日回购9.84万股,涉资约49.86万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135489982","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135489982?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:02","pubTimestamp":1784635348,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月21日发布公告,披露当日进行了股份购回。公告显示,公司当日回购98,400股普通股,占回购前已发行股本约0.01258%。每股购回价格介乎港币5.06元至5.08元,合计涉资港币49.86万元。回购完成后,公司已发行股份数目为782,374,980股,库藏股数目为9,380,100股。购回授权于2026年6月5日获通过,公司可根据该授权购回股份总数为78,372,528股,已累计购回1,350,300股。本次公告由董事王晓洁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B7月21日回购9.84万股,涉资约49.86万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272527","title":"加科思-B(01167)7月21日斥资49.86万港元回购9.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272527","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653272527?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:52","pubTimestamp":1784634762,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B(01167)发布公告,于2026年7月21日斥资49.86万港元回购9.84万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652267235","title":"港股异动 | 加科思-B(01167.HK)午后涨超8% JAB-23E73联合化疗试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652267235","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652267235?lang=zh_cn&edition=full","pubTime":"2026-07-20 14:12","pubTimestamp":1784527961,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652688822","title":"加科思-B(01167):完成泛KRAS抑制剂JAB-23E73联合化疗用于KRAS突变胰腺癌一线 治疗之Ib/III期临床试验在中国的首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652688822","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652688822?lang=zh_cn&edition=full","pubTime":"2026-07-20 06:42","pubTimestamp":1784500970,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B 发布公告,本公司的泛KRAS抑制剂JAB-23E73联合白蛋白结合型紫杉醇及吉西他滨用于KRAS突变胰腺癌一线治疗之Ib/III期临床试验在中国完成首例患者给药。本项研究的启动依托此前公布在本公司2025年度年度报告中并仍在推进的I期临床试验所取得的喜人初步临床数据。KRAS突变在胰腺癌中发生率极高。本项研究正式启动,是JAB-23E73研发进程中的重要里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4134","BMED","IBBQ","III","BK1161","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128857756","title":"加科思-B(01167)宣布JAB-23E73联合方案在华Ib/III期试验完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1128857756","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128857756?lang=zh_cn&edition=full","pubTime":"2026-07-20 06:41","pubTimestamp":1784500891,"startTime":"0","endTime":"0","summary":"2026年7月20日,加科思-B发布自愿公告称,其自主研发的口服泛KRAS抑制剂JAB-23E73联合白蛋白结合型紫杉醇及吉西他滨,用于KRAS突变胰腺癌一线治疗的Ib/III期临床试验已在中国完成首例患者给药。该研究基于加科思在2025年年度报告中披露并仍在推进的I期临床试验数据。加科思表示,KRAS突变在胰腺癌中发病率较高,此次研究正式启动是JAB-23E73研发进程的重要里程碑。公司提醒投资者,根据香港联交所证券上市规则第18A.05条,无法保证JAB-23E73最终能够成功开发及商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128799017","title":"加科思-B回购10.5万股股份,总额约48.78万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1128799017","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128799017?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:21","pubTimestamp":1784290917,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月17日发布公告,披露公司于香港联交所场内回购了105,000股,占回购前公司已发行股本的约0.01342%。据公告显示,本次回购价格区间介于每股港币4.64元至4.66元,合计耗资约48.78万港元。回购完成后,公司于2026年7月17日的已发行股份数变更为782,473,380股,库藏股则增加至9,281,700股,合并后公司股本总数仍为791,755,080股。公告称,上述回购基于2026年6月5日通过的股份回购授权进行,授权回购股份总数为78,372,528股,迄今已回购的股份累计1,251,900股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"加科思-B回购10.5万股股份,总额约48.78万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652288708","title":"加科思-B(01167)7月17日斥资48.8万港元回购10.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652288708","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652288708?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:19","pubTimestamp":1784290769,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B(01167)发布公告,于2026年7月17日斥资48.8万港元回购10.5万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182406145","title":"加科思-B回购约10.17万股股份,总额约49.87万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182406145","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182406145?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:50","pubTimestamp":1783950650,"startTime":"0","endTime":"0","summary":"加科思-B于2026年7月13日公布翌日披露报表,公司在香港联交所场内回购股份,涉及约101,700股普通股,约占当日公司现有已发行股份的0.01299%。最高回购价为每股4.92港元,最低回购价为每股4.90港元,合计支付约49.87万港元。回购完成后,公司已发行股份数量变更为约782,680,380股,库藏股增至约9,074,700股,合计已发行股本为约791,755,080股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B回购约10.17万股股份,总额约49.87万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651432112","title":"加科思-B(01167)7月13日耗资约49.87万港元回购10.17万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651432112","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651432112?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:47","pubTimestamp":1783950440,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B(01167)公布,2026年7月13日耗资约49.87万港元回购10.17万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134289117","title":"加科思-B回购10.11万股,耗资约49.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134289117","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134289117?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:50","pubTimestamp":1783601450,"startTime":"0","endTime":"0","summary":"加科思-B于2026年7月9日发布翌日披露报表,公布当日于香港联交所回购101,100股普通股,回购股份占回购前公司已发行股本约0.01291%。此次回购价格区间为每股港币4.93元至4.95元,合计支付约49.94万港元。公司表示,其回购授权于2026年6月5日获股东大会通过,授权回购股份总数为78,372,528股,截至目前已根据授权在香港联交所购回股份943,200股,约占当日获授权时已发行股本的0.12035%。公司确认已遵守香港联交所证券上市规则及相关法例的规定。本次公告由董事王晓洁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"加科思-B回购10.11万股,耗资约49.94万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156860148","title":"加科思-B:7月8日回购101,700股,耗资约49.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156860148","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156860148?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:42","pubTimestamp":1783518136,"startTime":"0","endTime":"0","summary":"加科思-B于2026年7月8日发布翌日披露报表,宣布于当天在香港联交所场内回购101,700股普通股,占公司截至该次回购前已发行股本的约0.01299%。根据公告,公司本次回购依据于2026年6月5日通过的购回授权进行,授权范围内可再购回78,372,528股,截至目前,累计在香港联交所及其他证券交易所已购回合共842,100股,占授权通过当日已发行股份约0.10745%。公司确认本次回购已遵守香港联交所相关上市规则及适用法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"加科思-B:7月8日回购101,700股,耗资约49.88万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649776999","title":"加科思-B(01167.HK)7月8日斥资49.9万港元回购10.17万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649776999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649776999?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:41","pubTimestamp":1783518082,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01167","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103038233","title":"加科思-B回购101,100股股份,合计耗资约49.92万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103038233","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103038233?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:28","pubTimestamp":1783420093,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月7日发布公告称,公司于当日在香港联合交易所回购101,100股股份,占回购前现有已发行股本的0.01291%。此次回购每股价格介乎港币4.92元至4.95元,总计支付对价约499,185港元。本次回购股份将被列作库存股份。本次回购完成后,公司已发行股份总数保持在791,755,080股,其中流通股份数为782,984,880股,库存股份数为8,770,200股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B回购101,100股股份,合计耗资约49.92万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649894529","title":"加科思-B(01167)7月7日斥资49.92万港元回购10.11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649894529","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649894529?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:21","pubTimestamp":1783419660,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B(01167)发布公告,于2026年7月7日,该公司斥资49.92万港元回购10.11万股股份,每股回购价4.92-4.95港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01167","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166069602","title":"加科思-B更新6月股份变动月报表,当月回购976,500股","url":"https://stock-news.laohu8.com/highlight/detail?id=1166069602","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166069602?lang=zh_cn&edition=full","pubTime":"2026-07-07 10:37","pubTimestamp":1783391830,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月7日发布截至2026年6月30日止的股份变动月报表,披露了公司注册股本及股份变动等情况。期末已发行股份总数为791,755,080股,其中,流通股份783,085,980股,库存股份8,669,100股。报告期内,公司无新增发行或注销股份,发生了累计976,500股的股份回购活动,并将所回购股份列作库存股份。截至本月底,公司确认已符合香港联合交易所有限公司相关公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189594505","title":"加科思-B:6月24日回购10.86万股,涉资约46.82万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189594505","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189594505?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:41","pubTimestamp":1782297681,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年6月24日发布公告,披露公司当日于香港联交所场内回购股票,共涉及普通股10.86万股,占当日前已发行股本的约0.01387%。此次回购的每股价格介乎港币4.29元至港币4.33元,合计耗资约46.82万港元。回购完成后,公司已发行股本由7.83194580亿股减少至7.83085980亿股,库藏股数增至866.91万股。公司同时披露,在本次回购后对应的30天内,不会新发行股份或出售、转让任何库藏股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"加科思-B:6月24日回购10.86万股,涉资约46.82万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645783894","title":"加科思-B(01167)6月24日斥资46.82万港元回购10.86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645783894","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645783894?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:38","pubTimestamp":1782297488,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B(01167)发布公告,于2026年6月24日,该公司斥资46.82万港元回购10.86万股股份,每股回购价4.29-4.33港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158124791","title":"加科思-B回购111,600股,涉资约49.89万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158124791","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158124791?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:01","pubTimestamp":1782122471,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年6月22日发布公告,称公司在香港联交所场内回购111,600股股份,占当日已发行股本约0.01425%。每股回购价介乎4.41港元至4.51港元,总金额约49.89万港元。公告显示,回购完成后,公司已发行股本变动为783,194,580股,库藏股数增至8,560,500股。公司提及,该回购基于2026年6月5日获得股东通过的购回授权,最多可在市场购回78,372,528股。公司确认已遵守香港联交所相关上市规则及适用法律法规。公告由公司董事王晓洁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B回购111,600股,涉资约49.89万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645902563","title":"加科思-B(01167)6月22日耗资约49.89万港元回购11.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645902563","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645902563?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:00","pubTimestamp":1782122452,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B(01167)公布,2026年6月22日耗资约49.89万港元回购11.16万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158681659","title":"加科思-B回购11.34万股股份,耗资约49.86万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158681659","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158681659?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:55","pubTimestamp":1781776555,"startTime":"0","endTime":"0","summary":"2026年6月18日,加科思药业集团有限公司发布公告,称当日于香港联合交易所场内回购普通股113,400股,约占公司已发行股本的0.01448%。每股回购价格介乎4.38港元至4.42港元,总涉资约49.86万港元。公告显示,公司于2026年6月5日获股东大会批准的回购授权总额为78,372,528股,截至目前累计回购股份419,100股,占授权通过当日已发行股本的0.05348%。公司确认已遵守香港联合交易所《证券上市规则》及相关法律法规要求。公告由董事王晓洁签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B回购11.34万股股份,耗资约49.86万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jacobiopharma.com","stockEarnings":[{"period":"1week","weight":0.0347},{"period":"1month","weight":0.1497},{"period":"3month","weight":-0.3541},{"period":"6month","weight":-0.233},{"period":"1year","weight":-0.2869},{"period":"ytd","weight":-0.2041}],"compareEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.0505},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0562},{"period":"1year","weight":0.0055},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"加科思药业集团有限公司是一家主要从事临床阶段新药研发的投资控股公司。该公司主要负责创新肿瘤疗法的自主发现和开发。该公司主要药物开发项目包括JAB-21822及JAB-3312临床阶段的变构SHP2抑制剂。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.0037},{"month":2,"riseRate":0.5,"avgChangeRate":0.158834},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.004688},{"month":4,"riseRate":0.666667,"avgChangeRate":0.034456},{"month":5,"riseRate":0.333333,"avgChangeRate":0.005017},{"month":6,"riseRate":0,"avgChangeRate":-0.071939},{"month":7,"riseRate":0.5,"avgChangeRate":0.071659},{"month":8,"riseRate":0.2,"avgChangeRate":0.005746},{"month":9,"riseRate":0.6,"avgChangeRate":-0.002238},{"month":10,"riseRate":0.2,"avgChangeRate":-0.065405},{"month":11,"riseRate":0.4,"avgChangeRate":0.020921},{"month":12,"riseRate":0.2,"avgChangeRate":-0.06824}],"exchange":"SEHK","name":"加科思-B","nameEN":"JACOBIO-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"加科思-B,01167,加科思-B股票,加科思-B股票老虎,加科思-B股票老虎国际,加科思-B行情,加科思-B股票行情,加科思-B股价,加科思-B股市,加科思-B股票价格,加科思-B股票交易,加科思-B股票购买,加科思-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}